The potential role of insulin-like growth factor-1 and zinc in brain growth of autism spectrum disorder children

Abstract

Get full access to this article

View all access options for this article.

References

Arora

Reichenberg

Willfors

et al . (2017) Fetal and postnatal metal dysregulation in autism. Nature Communications 8: 15493.

Bou Khalil

(2017) Is insulin growth factor-1 the future for treating autism spectrum disorder and/or schizophrenia? Medical Hypotheses 99: 23–25.

Courchesne

Campbell

Solso

(2011) Brain growth across the life span in autism: age-specific changes in anatomical pathology. Brain Research 1380: 138–145.

Hazlett

Munsell

et al . (2017) Early brain development in infants at high risk for autism spectrum disorder. Nature 542(7641): 348–351.

Hazlett

Poe

Gerig

et al . (2011) Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. Archives of General Psychiatry 68(5): 467–476.

Kim

Leventhal

(2015) Genetic epidemiology and insights into interactive genetic and environmental effects in autism spectrum disorders. Biological Psychiatry 77(1): 66–74.

Maggio

De Vita

Lauretani

et al . (2013) IGF-1, the cross road of the nutritional, inflammatory and hormonal pathways to frailty. Nutrients 5(10): 4184–4205.

Pfaender

Sauer

Hagmeyer

(2017) Zinc deficiency and low enterocyte zinc transporter expression in human patients with autism related mutations in SHANK3. Scientific Reports 7: 45190.

Redcay

Courchesne

(2005) When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biological Psychiatry 58(1): 1–9.

10.

Shcheglovitov

Shcheglovitova

Yazawa

(2013) SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 503(7475): 267–271.

11.

Vela

Stark

Socha

et al . (2015) Zinc in gut-brain interaction in autism and neurological disorders. Neural Plasticity 2015: 972791.